Thursday, 15 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· June 14, 2026

Warsh Caught Between Trump and Bond Market Betting on Rate Hikes

View original at finance.yahoo.com
Warsh Caught Between Trump and Bond Market Betting on Rate Hikes (Bloomberg) -- Just three weeks into the job, Federal Reserve Chairman Kevin Warsh is already facing an unusually high-stakes test…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • During his term as Fed governor, Warsh was a staunch hawk on monetary policy

    60% confidence
  • The Fed is widely expected to hold its benchmark rate steady in a range of 3.5% to 3.75% at this week's policy meeting

    60% confidence
  • Inflation is roaring back at the fastest pace in three years

    60% confidence
  • Kevin Warsh is in a very difficult position navigating conflicting pressures from the White House and bond markets

    60% confidence
  • The Federal Reserve was wrong to continue forecasting elevated inflation

    60% confidence
  • Artificial intelligence will unleash a significant disinflationary force on the economy by increasing productivity

    60% confidence
  • President Trump has called on the Federal Reserve to lower interest rates

    60% confidence
  • Investors have been dumping US Treasury bonds and piling into bets that the Fed will need to start raising rates by December

    60% confidence
  • If Warsh delivers a convincing message that the Fed is willing to shift back into inflation-fighting mode, Wall Street will likely be reassured about his commitment to the bank's political independence; failure to do so will rattle already-worried markets

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com